Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

The New York TimesMonday, November 24, 2025 at 10:18:18 PM
NegativeScience
Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
  • Novo Nordisk's trials of its diabetes and weight loss drug, Ozempic, have failed to demonstrate any positive effects on cognition or functioning in individuals with mild cognitive impairment or dementia, marking a significant setback for the company's ambitions in treating Alzheimer's disease.
  • The failure of Ozempic in these trials has led to a notable decline in Novo Nordisk's stock value, raising concerns among investors about the company's future prospects in the pharmaceutical market, particularly in the area of neurodegenerative diseases.
  • This development highlights the challenges faced by pharmaceutical companies in finding effective treatments for Alzheimer's, a condition that remains difficult to manage, and underscores the broader economic pressures impacting the healthcare sector, including fluctuating market conditions and investor sentiment.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended apps based on your readingExplore all apps
Continue Readings
Study links GLP-1 use to some pregnancy risks — but the study has key caveats
NeutralScience
A recent study suggests that individuals who have taken GLP-1 medications, such as Ozempic, may experience increased risks of adverse pregnancy outcomes. This finding raises concerns about the implications of these drugs for pregnant individuals, necessitating further research to clarify the risks involved.
New Studies of Dog DNA Shed Light on Pets and People
PositiveScience
New studies of canine genetics have revealed significant insights into the diversity of dog breeds and the evolving relationship between dogs and humans. These findings highlight the intricate genetic variations that have developed over time, shedding light on how dogs have adapted alongside people throughout history.
GLP-1 Pill Fails to Slow Alzheimer’s Progression in Clinical Trial
NegativeScience
Novo Nordisk's recent clinical trials of oral semaglutide, marketed as Ozempic and Wegovy, have shown that the drug does not slow the progression of Alzheimer's disease, marking a significant setback for the company's research efforts in this area.
In Michigan’s Upper Peninsula, Locals Fight for ‘The Right to Night’
PositiveScience
Residents of Michigan’s Upper Peninsula are advocating for the preservation of their night skies, particularly in Eagle Harbor, as industrialization threatens the region's celestial beauty. This movement, referred to as the fight for 'The Right to Night,' highlights the community's desire to protect their natural environment from light pollution and maintain the area's unique astronomical features.
These Hospitals Figured Out How to Slash C-Section Rates
PositiveScience
Hospitals have successfully implemented financial and social incentives to reduce the rates of C-sections, as reported by The New York Times. This approach encourages doctors to consider alternative birthing methods, thereby addressing concerns over the rising number of surgical deliveries.
Lemurs in Madagascar Face an Unexpected Killer
NegativeScience
Thousands of endangered lemurs in Madagascar are being hunted and consumed by affluent individuals, highlighting a troubling trend in wildlife exploitation. The bamboo lemur (Hapalemur occidentalis) is among the species affected by this unexpected threat to their survival.